Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Patent
1995-06-07
1999-03-02
Walsh, Stephen
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
530350, C07K 14705
Patent
active
058772758
ABSTRACT:
The invention features human CD11 recombinant or synthetic peptide capable of inhibiting a CD11/CD18-mediated immune response, a purified DNA encoding a human CD11b peptide, soluble heterodimeric molecules composed of a CD11 peptide and a CD18 peptide, and a method of controlling any phagocyte-mediated tissue damage such as that associated with reduced perfusion of heart tissue during acute cardiac insufficiency.
REFERENCES:
patent: 4840793 (1989-06-01), Todd, III et al.
patent: 5114842 (1992-05-01), Plow et al.
Arnaout et al., Blood 75:1037-1190.
Dana et al., J. Clin. Invest. 73:153-159 1984.
Arnaout et al., J. Clin. Invest. 74:1291-1300 1984.
Dana et al., The Journal of Immunology, vol. 137, No. 10, pp. 3259-3263, Nov. 15, 1986.
Mehra et al., Proc. Natl. Acad. Sci., USA, vol. 83, pp. 7013-7017, Sep. 1986.
Kishimoto et al., Cell, vol. 48, pp. 681-690, Feb. 27, 1987.
Pytela, The Embo Journal, vol. 7, No. 5, pp. 1371-1378, 1988.
Corbi et al., The Journal of Biological Chemistry, vol. 263, No. 25, pp. 12403-12411, Sep. 5, 1988.
Arnaout et al., New Eng. J. Med. 321:457 1985.
Todd et al., J. Clin. Invest. 74:1280 1984.
Arnaout et al., J. Clin. Invest. 72:171 1983.
Wallis et al., J. Immunol. 135:2323 1985.
Beatty et al., J. Immunol. 131:2913 1983.
Law et al., EMBO J. 6:915 1987.
Todd et al., Hybridoma 1:329 1982.
Hickstein et al., Proc. Nat'l. Acad. Sci. USA 86:275 1989.
Larson et al., J. Cell. Biol. 108:703 1989.
Cosgrove et al. Proc. Nat'l. Acad. Sci. USA 83:752 1986.
Sastre et al. Proc. Nat'l. Acad. Sci. USA 83:5644 1986.
Hutchings et al., Mature 348:639 1990.
Carlos et al., Immunol. Rev. 114:5, 1990.
Pierce et al., Biochem. Biophys. ACTA 874:368 1986.
Arnaout et al., J. Clin. Invest. 85:977 1990.
Ruoslahti et al., Science 238:491 1987.
Hynes et al., Cell 48:549 1987.
Bowie et al. 1990. Science 247: 1306-1310.
Miller, et al, 1987, "Purification and .varies.subunit N-terminal suquences of . . . " J. Immunol. 138:2381-83.
Tamkun, et al., 1986, "Structure of integrin, a glycoprotein involved in . . . " Cell vol. 46:271-282.
Arnaout, et al., 1988, J. Cell Biol. 106: 2153-2158.
Corbi, et al., 1987, EMBO Journal vol. 6: 4023-4028.
Simpson, et al., 1988, J. Clin. Invest. 81: 624-628.
Vedder, et al., 1988, J. Clin. Invest. 81:939-944.
Brown Karen E.
The General Hospital Corporation
Walsh Stephen
LandOfFree
Controlling cellular immune/inflammatory responses with .beta.2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlling cellular immune/inflammatory responses with .beta.2 , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlling cellular immune/inflammatory responses with .beta.2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-423825